Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aytu BioPharmaAYTU -2.93%42 Equity-to-Asset is 0.32 as of Mar. 2026, which is at its 10-year median of 0.32. GuruFocus rates AYTU with a GF Score™ of 42/100 and a GF Value™ of $0.89 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 1,008 Drug Manufacturers companies, Aytu BioPharma ranks worse than 81.94% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Aytu BioPharma's Total Stockholders Equity for the quarter that ended in Mar. 2026 was $35.14 Mil. Aytu BioPharma's Total Assets for the quarter that ended in Mar. 2026 was $111.69 Mil.
Therefore, Aytu BioPharma's Equity to Asset Ratio for the quarter that ended in Mar. 2026 was 0.32.
The historical rank and industry rank for Aytu BioPharma's Equity-to-Asset or its related term are showing as below:
AYTU'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.08 Med: 0.32 Max: 0.68
Current: 0.32
During the past 13 years, the highest Equity to Asset Ratio of Aytu BioPharma was 0.68. The lowest was 0.08. And the median was 0.32.
AYTU's Equity-to-Asset is ranked worse than 81.94% of 1008
companies
in the Drug Manufacturers industry
Industry Median: 0.6
vs AYTU: 0.32
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Aytu BioPharma Equity-to-Asset Related Terms
Aytu BioPharma Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Aytu BioPharma's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AYTU vs BFRI, TXMD, ETST: Equity-to-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Aytu BioPharma's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aytu BioPharma Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Aytu BioPharma's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Aytu BioPharma's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Aytu BioPharma's Equity to Asset Ratio for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aytu BioPharma (AYTU) has a Equity-to-Asset of 0.32 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Aytu BioPharma and its competitors. This is near median its historical median of 0.32. Over the past decade, Aytu BioPharma's Equity-to-Asset has ranged from 0.08 to 0.68. According to the industry distribution chart, Aytu BioPharma ranks #826 out of 1008 companies in the Drug Manufacturers industry, placing it in the top 81.9%.
Is Aytu BioPharma's Equity-to-Asset too high?
Aytu BioPharma's current Equity-to-Asset of 0.32 is near median its 10-year median of 0.32. Over the past 10 years, this metric has ranged from a low of 0.08 to a high of 0.68. The Drug Manufacturers industry median Equity-to-Asset is 0.60. Aytu BioPharma's value of 0.32 is 46.7% below this industry median. Based on the distribution chart, Aytu BioPharma ranks #826 out of 1008 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Aytu BioPharma has a GF Score™ of 42/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aytu BioPharma's Equity-to-Asset compare to BFRI and TXMD?
According to the Drug Manufacturers industry distribution chart, Aytu BioPharma ranks #826 out of 1008 companies for Equity-to-Asset. This places Aytu BioPharma in the lower half of its industry. The industry median Equity-to-Asset is 0.60. Aytu BioPharma's value of 0.32 is 46.7% below this benchmark. Historically, Aytu BioPharma's own Equity-to-Asset has ranged from 0.08 to 0.68 over the past decade. While the company's 10-year median is 0.32 vs. the industry median of 0.60, Aytu BioPharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.60, based on 1,008 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aytu BioPharma's current Equity-to-Asset of 0.32 is 46.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Aytu BioPharma and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aytu BioPharma's current Equity-to-Asset is 0.32, which is near median its own 10-year median of 0.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aytu BioPharma stock overvalued right now?
Based on GuruFocus' analysis, Aytu BioPharma (AYTU) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.89, compared to a current price of $1.99 — trading 123.6% above its estimated fair value. The current Equity-to-Asset is 0.32, which is near median its 10-year median of 0.32 and 46.7% below the Drug Manufacturers industry median of 0.60. Aytu BioPharma's overall GF Score™ is 42/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Aytu BioPharma (AYTU), the current Equity-to-Asset is 0.32 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aytu BioPharma (AYTU) Overvalued in 2026?
Based on GuruFocus' analysis, Aytu BioPharma stock appears to be overvalued.
The current stock price of $1.99 is trading 123.6% above its estimated GF Value™ of $0.89.
GuruFocus considers Aytu BioPharma to be Significantly Overvalued.
Key valuation signals for AYTU:
Equity-to-Asset: 0.32 (near median its 10-year median of 0.32)
GF Value™: $0.89 vs. price of $1.99 (123.6% above fair value)
Industry Position: 46.7% below the Drug Manufacturers median (#826 of 1008)
No single metric tells the full story. See the AYTU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.
42GF Score
Get the complete analysis for AYTU
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AYTU has been successfully added to your 
